Lead Product(s): KHK4083
Therapeutic Area: Dermatology Product Name: KHK4083
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $1,250.0 million Upfront Cash: $400.0 million
Deal Type: Collaboration June 01, 2021
KHK4083 is an anti-OX40 fully human monoclonal antibody discovered by Kyowa Kirin and engineered with Kyowa Kirin’s patented POTELLIGENT® defucosylation technology to enhance its antibody-dependent cellular cytotoxicity (ADCC) activity.